ArticleCureus2025
Outcomes of Platelet-Rich Plasma Versus Dextrose 10% Prolotherapy in the Treatment of Osgood-Schlatter Disease: A Retrospective Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsgood-Schlatter disease (OSD) is a common overuse injury affecting adolescents engaged in physical activities. While conservative treatment remains the standard, refractory cases may benefit from regenerative therapies, such as platelet-rich plasma (PRP) and 10% dextrose prolotherapy (DPT). Comparative evidence between these interventions in OSD is limited.
objectivesTo compare the 12-week clinical effectiveness of single PRP injection versus triple DPT injection series in adolescents with refractory OSD, specifically evaluating pain reduction (primary), functional improvement (primary), return-to-sports duration (secondary), and patient satisfaction (secondary).
methodsThis retrospective comparative cohort study included 40 adolescents with radiologically and clinically diagnosed refractory OSD treated between 2022 and 2024. Treatment allocation was non-randomized based on availability and patient preference. Patients received either a single PRP injection (n=20) or a triple DPT injection series (n=20). Primary outcomes were pain reduction (visual analog scale) and functional improvement (Lysholm Knee Score) measured at baseline, four, eight, and 12 weeks. Secondary outcomes included return-to-sports duration and patient satisfaction. Statistical analysis employed hierarchical Bonferroni correction for primary outcomes (adjusted α=0.0125) with secondary outcomes analyzed at α=0.05.
resultsPRP demonstrated greater pain reduction (VAS: 7.9±0.8 to 1.8±0.9 vs DPT: 7.6±1.0 to 3.4±1.1, p<0.001, Cohen's d=1.60, 95% CI: 1.15-2.05) and functional improvement (Lysholm: 50.8±6.2 to 91.5±4.8 vs 52.1±7.0 to 82.4±5.6, p<0.001, Cohen's d=1.71, 95% CI: 1.25-2.17). PRP patients returned to sports faster (6.1±1.2 vs 8.5±1.3 weeks, p<0.001, Cohen's d=1.94) with higher satisfaction rates (90% vs 65%, p=0.039, OR=5.54, 95% CI: 1.01-30.2).
conclusionIn this small retrospective study, PRP showed better short-term outcomes than DPT for refractory OSD, including greater pain reduction and faster return to sports. Further randomized controlled trials are warranted to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.